TARS vs TNGX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TARS · Tarsus Pharmaceuticals$68.60 ▲ 1.60%
TNGX · Tango Therapeutics$21.50 ▲ 3.02%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TARS -5.8%
- TNGX +171.1%
Head to head
| Metric | TARS | TNGX |
|---|---|---|
| Price | $68.60 | $21.50 |
| Change today | ▲ 1.60% | ▲ 3.02% |
| Market cap | $3.38B | $3.63B |
| Return, 3 months | +1.2% | -22.3% |
| Return, year to date | -16.2% | +142.7% |
| Return, 1 year | +0.5% | +173.2% |
| P/E (TTM) | – | – |
| P/B | 32.5 | 3.5 |
| P/E percentile vs own 5y | 2nd | 8th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +69.4% | -100.0% |
| Net profit growth (YoY) | +8.8% | -42.4% |
| Gross margin | 93.3% | – |
| Operating margin | -8.0% | -253.4% |
| Net margin | -7.7% | -229.9% |
| Return on equity | -13.7% | -21.3% |
| Analyst target vs. price | +46.0% | +120.9% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 42 | 44 |
| 30-day volatility | 41.6% | 87.6% |
| Max drawdown, 1 year | -32.0% | -36.6% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TNGX is the largest of the group by market value.
- TNGX has returned the most over the past year.
- TARS is growing revenue fastest.
- TARS keeps the most profit per dollar of sales.
- TARS has been the calmest stock over the last 30 days.